RxDoctor Payments Data

James Williams, MD

Infectious Disease · Wailuku, HINPI 1497753594

Payments from drug & device makers

What this record shows

Almost everything reported here is food and beverage — 96.4% of the total across 108 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 12 manufacturers reported payments, led by Insmed, Inc. at 30.5% of the total. 2025 is the largest year on record at $896, 4.8 times the $185 reported in 2019.

$3,187in general payments, 2019–2025

Across 108 payments — averaging $29.51 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Insmed, Inc.$971
  • Gilead$503
  • Mimedx Group, Inc.$503
  • AbbVie$437
  • Organogenesis Inc.$422
  • Viiv Healthcare Company$226
  • plus $125 from 6 others

What the payments were for

  • Food & beverage$3,07196%
  • Education$1154%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$3,187 in reported general payments places this provider in the 75th percentile of 28 infectious disease providers in Hawaii.

See all infectious disease providers in Hawaii

Medicare billing

Part B allowed, 2024
$29,942
Medicare patients
85
Services billed
361

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
ArikayceAmikacin Liposomal/Neb.Accessr25$363,960
NuzyraOmadacycline Tosylate12$178,836
OdefseyEmtricitab/Rilpiviri/Tenof Ala14$69,884
BiktarvyBictegrav/Emtricit/Tenofov Ala12$55,819
TriumeqAbacavir/Dolutegravir/Lamivudi11$47,007
Cephalexin12$643
Ciprofloxacin Hcl15$137

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Insmed, Inc.Arikayce$971$363,96025 claims
GileadBiktarvy$503$55,81912 claims
Viiv Healthcare CompanyTriumeq$226$47,00711 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 28 infectious disease providers in Hawaii.

Other infectious disease in Wailuku

See the full list for Hawaii

Where these figures come from

Is this you, or does something look wrong? →